Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lure Of Niche Drugs Leads India's Cadila To Buy Troubled KV Pharma's Generic Arm For $60 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

With the acquisition of Nesher Pharmaceuticals, Cadila hopes to gain a strong footing in the high-barrier but lucrative controlled substance market, which is estimated at $7 billion.
Advertisement

Related Content

KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?
KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?
Cadila Heathcare Chairman Pankaj Patel On Consolidation In The Indian Industry And Why It's Not Happening Locally: An Interview With PharmAsia News

Topics

Advertisement
UsernamePublicRestriction

Register

PS072401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel